OPM publishes its 2025 half-yearly report

OPM publishes its 2025 half-yearly report

Dijon, France, October 9, 2025, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces today that its half-yearly financial report as of June 30, 2025 has been filed with the Financial Markets Authority.